Compare First Citizens BancShares Inc (FCNCA) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Gilead Sciences, Inc. — how do they compare? First Citizens BancShares Inc trades at $2,066.27 (market cap $22.94B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 8× First Citizens BancShares Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and Gilead Sciences, Inc. for 111 Days on average.
| FCNCA | GILD | |
|---|---|---|
Market Cap | $22.94B | $182.40B |
Volume | 91,668 | 4,469,821 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $155.80 |
52-Week Low | $1.64K | $116.74 |
Typical Hold Time | 29 Days | 111 Days |
Dividend Yield | 0.41% | 2.23% |
Enterprise Value | — | $205.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,071.56, down 0.79% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with a P/E of 11.11 and net income margin of 25.23%, and has beaten EPS estimates for the last three quarters. Recent corporate actions include a $2.10 dividend and expansion through branch acquisitions and new financing initiatives.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but near-term technical weakness and high institutional hold ratings suggest caution. Key risks include execution of growth initiatives and broader economic pressures on banking.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
